AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9538647
Drug: Hemodialysis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodialysis with the presence of heparin
Trial: 29532196
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) using GaAlAs diode laser (780 nm, 2 J/spot) applied immediately after surgery and every 24 hours for 3 days.
Trial: 29532196
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no laser therapy).
Trial: 23558454
Drug: Orofacial regulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orofacial regulation therapy
Trial: 23558454
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no mimicry therapy)
Trial: 18701642
Drug: Pycnogenol (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pycnogenol (150 mg daily for 3 months)
Trial: 12818461
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol
Trial: 12818461
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg estradiol
Trial: 10083765
Drug: Gemfibrozil 300
RxNorm normalized name: gemfibrozil 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 300 mg twice per day
Trial: 7729302
Drug: Euglycemic hyperinsulinemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycemic hyperinsulinemic clamp (40 mU insulin.m-2.min-1)
Trial: 7729302
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (50 ml isotonic saline)
Trial: 2292327
Drug: 0.1% mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% mometasone furoate cream applied once daily
Trial: 2292327
Drug: 0.1% betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% betamethasone valerate cream applied twice daily
Trial: 30517622
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (TVP-)
Trial: 21057356
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (transfusion if hemoglobin <7.0 g/dL)
Trial: 21057356
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (transfusion if hemoglobin <9.5 g/dL)
Trial: 20581790
Drug: TzCOAD (150-375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TzCOAD (150-375 mg)
Trial: 776152
Drug: Piracetam (pyrrolidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (pyrrolidine acetamide) at a dose of 80 mg/kg/day for 10 weeks.
Trial: 776152
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving customary treatment only.
Trial: 29968937
Drug: Fecal immunochemical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal immunochemical test (FIT) with cut-off levels 20 μg Hb/g and 40 μg Hb/g for one sample
Trial: 29968937
Drug: Fecal immunochemical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal immunochemical test (FIT) with mean of two samples at cut-off 40 μg Hb/g and 80 μg Hb/g
Trial: 29968937
Drug: Fecal immunochemical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal immunochemical test (FIT) in women with lowered cut-off from 40 to 20 μg Hb/g
Trial: 29510001
Drug: Tildrakizumab IV
RxNorm normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tildrakizumab IV doses of 0.1, 0.5, 3 and 10 mg/kg
Trial: 29510001
Drug: Tildrakizumab SC
RxNorm normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tildrakizumab SC doses of 50 or 200 mg
Trial: 17414240
Drug: 20-mg fluoxetine
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mg fluoxetine
Trial: 17414240
Drug: 40-mg fluoxetine
RxNorm normalized name: fluoxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-mg fluoxetine
Trial: 15840751
Drug: Monophasic oral
RxNorm normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic oral contraceptive pill with lower dose of norethisterone
Trial: 15840751
Drug: Monophasic oral
RxNorm normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic oral contraceptive pill with higher dose of norethisterone
Trial: 12402610
Drug: Dressing film
RxNorm normalized name: DRESSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dressing film method (Group A) - exit site cleaned with povidone iodine solution once weekly, covered with gauze, sealed with dressing film
Trial: 12402610
Drug: Dressing film
RxNorm normalized name: DRESSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dressing film method (Group B) - exit site cleaned with povidone iodine solution once every 2 weeks, covered with gauze, sealed with dressing film
Trial: 12402610
Drug: Dressing film
RxNorm normalized name: DRESSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dressing film method (Group C) - exit site cleaned with povidone iodine solution once every 3 weeks, covered with gauze, sealed with dressing film
Trial: 12402610
Drug: Dressing film
RxNorm normalized name: DRESSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dressing film method (Group D) - exit site cleaned with povidone iodine solution once every 4 weeks, covered with gauze, sealed with dressing film
Trial: 12402610
Drug: Dressing film
RxNorm normalized name: DRESSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dressing film method (Group E) - exit site cleaned with povidone iodine solution once every 5 weeks, covered with gauze, sealed with dressing film
Trial: 12402610
Drug: Dressing film
RxNorm normalized name: DRESSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dressing film method (Group F) - exit site cleaned with povidone iodine solution once every 6 weeks, covered with gauze, sealed with dressing film
Trial: 12402610
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - exit site cleaned with povidone iodine solution daily, gauze dressing applied
Trial: 7881645
Drug: Continuous nebulization
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous nebulization of terbutaline (16 mg over 8 hours)
Trial: 7881645
Drug: Intermittent nebulization
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent nebulization of terbutaline (4 mg every 2 hours for 20 minutes)
Trial: 417893
Drug: High pressure
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High pressure oxygen (HPO) with six fractions of 600 rad maximum tissue dose
Trial: 417893
Drug: Air at
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air at atmospheric pressure with conventional small fraction daily radiotherapy
Trial: 28364091
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure treatment (targeting systolic BP <120 mm Hg)
Trial: 28364091
Drug: Standard blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard blood pressure treatment (targeting systolic BP <140 mm Hg)
Trial: 21480207
Drug: INCB018424 (JAK1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB018424 (JAK1 and JAK2 inhibitor)
Trial: 11734429
Drug: Budesonide (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (800 microg twice a day)
Trial: 9413293
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (13 to 15 mg/kg daily)
Trial: 31147684
Drug: Volumetric modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volumetric modulated arc therapy (VMAT) for GYN, rectal, H&N, and prostate cancer
Trial: 31147684
Drug: Volumetric modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volumetric modulated arc therapy (VMAT) for prostate cancer
Trial: 28814394
Drug: Mediterranean/low-carbohydrate (MED/LC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean/low-carbohydrate (MED/LC) diet plus 28 g walnuts/d
Trial: 23395779
Drug: 250ml beetroot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250ml beetroot juice daily (active)
Trial: 21214895
Drug: Tele‐health supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tele‐health supported Community COPD Service (two home visits with a specialist COPD clinician and daily tele‐monitoring over eight weeks)
Trial: 19172536
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of 17beta-estradiol (E(2) group)
Trial: 17175485
Drug: Fetoscopic laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fetoscopic laser therapy
Trial: 10740633
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose CDDP plus 5-FU regimen
Trial: 10740633
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy group (MMC and UFT)
Trial: 6685628
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of [3H]‐dibromodulcitol (400 mg/m2)
Trial: 6685628
Drug: Three smaller
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three smaller daily oral doses of [3H]‐dibromodulcitol (150‐180 mg/m2)
Trial: 29894926
Drug: Subcutaneous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous saline irrigation
Trial: 19786378
Drug: Nattokinase combined
RxNorm normalized name: Nattokinase
DrugBank: Nattokinase (DB15329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nattokinase combined with red yeast rice (RYR) extract (300 mg of extract/capsule)
Trial: 19786378
Drug: Nattokinase mono
RxNorm normalized name: Nattokinase
DrugBank: Nattokinase (DB15329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nattokinase mono formula (50 mg/capsule)
Trial: 11375838
Drug: Patient-controlled IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled IV meperidine (50 mg/h or more)
Trial: 11375838
Drug: Patient-controlled IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled IV meperidine (<50 mg/h)
Trial: 8215265
Drug: Ceftriaxone (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (75 mg/kg for children, 4 g for adults) for 5 days
Trial: 8215265
Drug: Chloramphenicol (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol (60 mg/kg/day until defervescence, then 40 mg/kg/day) for 14 days
Trial: 3114803
Drug: Promethazine (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine (12.5 mg, 25 mg)
Trial: 3114803
Drug: Cinnarizine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine (30 mg)
Trial: 25624389
Drug: Clonidine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (5 μg/kg per day, divided into 8 doses, with possible dose escalation to maximum of 12 μg/kg per day)
Trial: 25624389
Drug: Morphine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.4 mg/kg per day, with possible dose escalation to maximum of 1 mg/kg per day)
Trial: 20873903
Drug: Guided self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided self-help based on cognitive behavioral therapy (CBTgsh)
Trial: 18258639
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (792 mg/d)
Trial: 16377385
Drug: Allopurinol, 100
RxNorm normalized name: Allopurinol, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol, 100 to 300 mg/d
Trial: 9264767
Drug: Leuprorelin 11.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprorelin 11.25 mg every three months
Trial: 9264767
Drug: Leuprorelin 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprorelin 3.75 mg monthly
Trial: 7886558
Drug: SK therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SK therapy
Trial: 7886558
Drug: rt-PA therapy
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rt-PA therapy
Trial: 2429076
Drug: tibalosine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tibalosine 150 mg daily for 1 week
Trial: 2429076
Drug: naloxone (opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naloxone (opioid receptor antagonist)
Trial: 24418368
Drug: 50 IU
RxNorm normalized name: Pegaspargase 750 IU/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 IU kg(‐1) twice‐weekly prophylaxis regimen
Trial: 24418368
Drug: 100 IU
RxNorm normalized name: Vitamin E 100 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 IU kg(‐1) once‐weekly prophylaxis regimen
Trial: 20108160
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and Magnesium (Ca/Mg)
Trial: 12845235
Drug: PMX-F treatment
RxNorm normalized name: F-15599
DrugBank: F-15599 (DB16936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMX-F treatment (group A, n = 10)
Trial: 12845235
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (group B, n = 10)
Trial: 10827659
Drug: Topical regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical regular insulin (Iletin‐II) applied four times a day until healed
Trial: 10827659
Drug: Solution containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution containing the same amount of zinc
Trial: 8690827
Drug: Clomipramine (100‐250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (100‐250 mg/day)
Trial: 3908497
Drug: 0.03% aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% aqueous solution of Sanguinaria extract (active mouthrinse)
Trial: 3908497
Drug: Placebo preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo preparation (aqueous solution with similar color and taste)
Trial: 10624908
Drug: Acetaminophen 750
RxNorm normalized name: acetaminophen 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 750 mg
Trial: 8540713
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B colloidal dispersion (dose levels ranging from 0.5 to 8.0 mg/kg of body weight)
Trial: 1950383
Drug: Metoprolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (50 to 200 mg per day)
Trial: 7045606
Drug: cinoxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cinoxacin (500 mg every 12 hours)
Trial: 7045606
Drug: co-trimoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co-trimoxazole (160 mg trimethoprim, 800 mg sulphamethoxazole every 12 hours)
Trial: 31623250
Drug: 0.25 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 g/kg bodyweight DSP
Trial: 31623250
Drug: 0.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg bodyweight DSP
Trial: 31623250
Drug: 360 g
RxNorm normalized name: OATMEAL 0.025 g in 360 g TOPICAL SHAMPOO [DHT X]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 g of 10% DSB
Trial: 31623250
Drug: 360 g
RxNorm normalized name: OATMEAL 0.025 g in 360 g TOPICAL SHAMPOO [DHT X]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 g of 15% DSB
Trial: 31623250
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg bodyweight DSE
Trial: 31623250
Drug: 60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg bodyweight DSE
Trial: 27657985
Drug: Biosimilar recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosimilar recombinant human growth hormone (r-hGH; Somatotropin)
Trial: 27657985
Drug: Reference recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference recombinant human growth hormone (Genotropin®)
Trial: 23647408
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/day) for 6 weeks
Trial: 17277729
Drug: Healthy controls
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy controls (not specified treatment)
Trial: 7794079
Drug: TRAM flap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRAM flap breast reconstruction with radiation treatment
Trial: 7794079
Drug: TRAM flap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRAM flap breast reconstruction without radiation treatment
Trial: 28860712
Drug: Prophylaxis of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis of constipation (lactulose 10 mL twice daily)
Trial: 22795617
Drug: Kirtan Kriya
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kirtan Kriya Meditation (KKM) for 12 min daily for 8 weeks
Trial: 22795617
Drug: Relaxing Music
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxing Music (RM) listening for 12 min daily for 8 weeks
Trial: 15192072
Drug: rLH 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rLH 75 IU daily from GnRH antagonist initiation to hCG injection
Trial: 11682661
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ramipril and felodipine ER (R+F)
Trial: 10771837
Drug: Hyperglycemia (glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemia (glucose level > or = 150 mg/dl)
Trial: 3277475
Drug: Intravenous amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amphotericin B (0.2 to 2 mg/kg total dose) for 2 to 6 days
Trial: 28807030
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + Ascorbic Acid
Trial: 28807030
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + Acetylsalicylic Acid
Trial: 28807030
Drug: Metformin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin alone (Control)
Trial: 23715360
Drug: Salbutamol +
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol + Ipratropium bromide (3 doses of 2.5mg Salbutamol and 500mcg Ipratropium bromide)
Trial: 23715360
Drug: Salbutamol only
RxNorm normalized name: Salbutamol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol only (3 doses of 2.5mg)
Trial: 22019576
Drug: Topiramate (4-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (4-week titration starting at 25 mg/day to a maximum of 100 mg/day followed by an 8-week maintenance)
Trial: 17954698
Drug: Ceftobiprole 500
RxNorm normalized name: ceftobiprole medocaril sodium 667 MG (equivalent to ceftobiprole 500 MG) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftobiprole 500 mg every 12 h
Trial: 17306393
Drug: Postoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiotherapy (RT) in addition to adjuvant systemic therapy
Trial: 9164811
Drug: Standard intravenous-feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous-feeding solutions
Trial: 9164811
Drug: Aluminum-depleted intravenous-feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum-depleted intravenous-feeding solutions
Trial: 9164811
Drug: Standard intravenous-feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous-feeding solutions (subgroup with no neuromotor impairment)
Trial: 9164811
Drug: Aluminum-depleted intravenous-feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum-depleted intravenous-feeding solutions (subgroup with no neuromotor impairment)
Trial: 30882151
Drug: adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adherence to medication
Trial: 18515918
Drug: Fixed higher-dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed higher-dose budesonide/formoterol (FHDBF)
Trial: 18515918
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose fluticasone/salmeterol (FDFS)
Trial: 16223399
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of magnesium sulphate 5% (1.0 ml)
Trial: 16223399
Drug: 1.0 ml
RxNorm normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 ml of preservative‐free 0.9% sodium chloride
Trial: 10208945
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of salbutamol by jet nebuliser
Trial: 10208945
Drug: Up to
RxNorm normalized name: Nubasics Soup Tomato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 10 puffs of salbutamol 100 microg by metered dose inhaler and spacer
Trial: 1693335
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose oral treatment